RE: Updated March 8, 2008/pfizer still developing pmed dna herpes vaccine?
Just found this out from pfizer's
Our Commitment to Biotherapeutics /
Our Investment in Biotherapeutics
From the front to the back cover of our 2007 annual report, the importance of biotherapeutics to Pfizer is front and center. And the reason is clear. By establishing the biotech culture inside Pfizer, and opening and supporting a growing area of research, we believe we can bring more innovative therapies to patients around the world.
A large part of any investment is action and follow-through. And we are following through by creating a small, agile research unit in Biotherapeutics Research, advancing our biologicals and vaccines portfolios that hold tremendous promise in changing the way diseases are treated — and prevented. We also believe there is tremendous potential in forging new collaborations with scientists around the world and we have a fresh commitment to finding the best science outside our walls.
While we continue to invest and grow our internal capabilities, we will look to invest in relationships with academics, institutions and organizations who can help us advance our cause. As well as building your own partnerships, you will also have access to Pfizer's long standing collaborations, for example, our $100 million collaboration with the Scripps Institute in California.
This work will be backed up with our continued investment strategy. One example of the benefit of this approach is our 2006 acquisition of UK-based PowderMed Ltd. (PowderMed), a pioneer in the particle-mediated epidermal delivery of DNA vaccines. This technology platform may provide significant advantages over both traditional vaccines and “next-wave” cell-based vaccines. PowderMed’s needle-free delivery system uses pressurized helium to place DNA-coated microscopic gold particles into the first layer of skin. This generates both antibody and cell-mediated immune responses. Our researcher supports a belief that eliciting two immune responses, rather than one as in the case of traditional vaccines, will vastly increase vaccine effectiveness. Two influenza vaccines and a genital herpes vaccine are now in our development pipeline as a result of our partnership with our PowderMed colleagues.
Pfizer's chief executive, Jeffrey B. Kindler said in a statement that the move was aimed at “broadening health care solutions for patients” and in all our investments broadening health care solutions will continue to be our aim – whether this is through internal hiring, fostering scientific partnerships or by allowing our scientists access to vital technologies through licensing or acquisitions.
Our dedication to biotherapeutics is strong and unwavering. And we invite you to be a part of our team as move forward and change the world of medicine.
> View Our Positions > Join Our Biotherapeutics Research Network
As this was already in phase 1A/2 development so this could be brought to market in a faster time manner if pfizer does indeed progress the testing of this!! They do list it as in their "pipeline" very good news! Biotherapeutics. I did email them on this and they said they were not at liberty to discuss future developments at this time?
Lets hope for the best!